Get In Touch

By sharing my contact details, I hereby agree that Indiabulls and/or its group entities or their authorised representatives may contact me to understand my interest in the selected product and/or services or for customer survey, etc.

NIFTY 10980.45 img -27.60

SENSEX 36373.44 img -146.52

GOLD 29729.00

SILVER 37882.00

1 USD / INR 68.63

Attention Investors! "Prevent Unauthorised Transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of Investors."           Attention Investors! "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day. Issued in the interest of investors."           "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."           "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."           "As per SEBI guidelines, old DIS cannot be accepted for execution of instruction with effect from 07-01-2016. Kindly submit requisition slip / letter for issuance of new DIS booklet at our corporate office address to avoid rejection of your instruction(s) on or after 07-01-2016.”            "In accordance with the Union Budget 2017-18 announcement, SEBI has advised to link Aadhar with individual demat accounts. Kindly submit details of Aadhar number along with copy of Aadhar Card.”          

Market News

  • 13


    Divi`s Laboratories surges 24.21% in four sessions

    The stock had surged 11.83% to Rs 804.80 yesterday, 12 September 2017. The stock has galloped 24.21% in four sessions to its ruling price, from a close of Rs 694.75 on 7 September 2017.

    Meanwhile, the S&P BSE Sensex was up 113.99 points, or 0.35% to 32,272.65.

    High volume was witnessed on the counter. On the BSE, 8.36 lakh shares were traded in the counter so far, compared with average daily volumes of 2.3 lakh shares in the past one quarter. The stock had hit a high of Rs 863.15 and a low of Rs 793.05 so far during the day. The stock had hit a record high of Rs 1,380 on 16 September 2016. The stock had hit a 52-week low of Rs 533.10 on 29 May 2017.

    The stock had outperformed the market over the past one month till 12 September 2017, gaining 28.39% compared with the Sensex`s 3.03% gains. The stock had also outperformed the market over the past one quarter, rising 24.29% as against the Sensex`s 3.42% rise. The scrip had, however, underperformed the market over the past one year, falling 38.27% as against the Sensex`s 13.42% rise.

    The large-cap company has equity capital of Rs 53.09 crore. Face value per share is Rs 2.

    The US Food and Drug Administration (USFDA) is reportedly inspecting the Unit II of Divi`s Laboratories` Visakhapatnam facility. The inspection which started on Monday, 11 September 2017 is expected to conclude in a week`s time according to the report.

    The USFDA had issued an import alert on the Unit II of the company in March and a warning letter to the same in May. The plants that are on FDA`s import alert are not permitted to export drugs to the US. However, after receiving clearance from the European regulatory, it is speculated that the USFDA inspection of Unit II will conclude smoothly.

    Divi`s Laboratories had said in April that USFDA had exempted some more products manufactured at the company`s Unit-II at Visakhapatnam from the import alert issued under clauses 66-40 & 99-32 of the FDA regulations.

    Divi`s Laboratories` net profit fell 41.5% to Rs 176.54 crore on 19.3% decline in net sales to Rs 821.20 crore in Q1 June 2017 over Q1 June 2016.

    Divi`s Laboratories is primarily engaged in the manufacture of active pharmaceutical ingredients (APIs) & intermediates for generics; custom synthesis of API`s and advanced intermediates for discovery compounds for pharma giants; building blocks for peptides; building blocks for nucleotides; carotenoids; and chiral ligands.

    Powered by Capital Market - Live News

Copyright © 2017. All Rights Reserved. Indiabulls Ventures Limited. | Privacy Policy | | Bechmark Rates

Indiabulls Ventures Limited. [Corporate Identification Number for IVL: L74999DL1995PLC069631]
SEBI Reg No: INZ000007534 | NSE Membership No: 08756 [CM, FNO, CDS] | BSE Membership No: 907 [CM, FNO]
Indiabulls Commodities Ltd. - [Corporate Identification Number for ICL: U74999DL2003PLC122874]
SEBI Reg No: INZ000036136 | MCX: MEMBER CODE: 12835 | NCDEX: MEMBER CODE: 10

Site best viewed in IExplorer 10+ | Chrome | Firefox